Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226690 · ClinicalTrials.gov registry record · Phase 1
Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04226690: Completed Phase 1 study, sponsored by Yale University.
NCT04226690 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04226690, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination with Tetrahydrocannabinol and matched Placebo (PLA).
Primary Outcome
Change in provoked pain ratings on day 1 and day 7 on visual analog scale of pain (range 0-10)
Interventions
- DRUG Active CBD/THC Dose 1
- DRUG Active CBD/THC Dose 2
- DRUG matched placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
What the finished NCT04226690 record still lists
NCT04226690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 3 interventions - of which Active CBD/THC Dose 1 is the first listed.
NCT04226690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04226690 about?
NCT04226690 is a clinical study titled "Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products". This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination ...
What is the current status of trial NCT04226690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-11-15. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04226690?
The interventions under investigation include: Active CBD/THC Dose 1 (DRUG), Active CBD/THC Dose 2 (DRUG), matched placebo comparator (DRUG).
Who is sponsoring clinical trial NCT04226690?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04226690's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI